<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Brainsway Ltd — News on 6ix</title>
    <link>https://6ix.com/company/brainsway-ltd</link>
    <description>Latest news and press releases for Brainsway Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 13 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/brainsway-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836271978dffbe2df143e1a.webp</url>
      <title>Brainsway Ltd</title>
      <link>https://6ix.com/company/brainsway-ltd</link>
    </image>
    <item>
      <title>BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham &amp; Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a g</description>
    </item>
    <item>
      <title>Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants</title>
      <link>https://6ix.com/company/brainsway-ltd/news/neurolief-secures-additional-dollar6-million-investment-following-fda-approval-of-prolivtmrx-expanding-access-to-brain-neuromodulation-therapy-for-patients-with-inadequate-response-to-antidepressants</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/neurolief-secures-additional-dollar6-million-investment-following-fda-approval-of-prolivtmrx-expanding-access-to-brain-neuromodulation-therapy-for-patients-with-inadequate-response-to-antidepressants</guid>
      <pubDate>Mon, 30 Mar 2026 11:30:00 GMT</pubDate>
      <description>Neurolief, a medical technology company developing neuromodulation therapies for mental health conditions, today announced a $6 million milestone-based investment from BrainsWay Ltd., following FDA Premarket Approval (PMA) of its Proliv™Rx brain neuromodulation system. The investment reflects growing recognition of the need for accessible, clinically validated treatment options for adults whose depression has not adequately improved with antidepressant medication.</description>
    </item>
    <item>
      <title>BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-completes-additional-dollar6-million-milestone-based-investment-in-neurolief-ltd-following-fda-approval-of-prolivtmrx-system-for-mdd</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-completes-additional-dollar6-million-milestone-based-investment-in-neurolief-ltd-following-fda-approval-of-prolivtmrx-system-for-mdd</guid>
      <pubDate>Thu, 26 Mar 2026 11:30:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. (“Neurolief”). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief&apos;s P</description>
    </item>
    <item>
      <title>BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-completes-revenue-based-milestone-investment-into-axis-integrated-mental-health</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-completes-revenue-based-milestone-investment-into-axis-integrated-mental-health</guid>
      <pubDate>Thu, 19 Mar 2026 11:30:00 GMT</pubDate>
      <description>BrainsWay’s investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to careBURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. (“Axis Integrated Men</description>
    </item>
    <item>
      <title>BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
      <pubDate>Wed, 11 Mar 2026 11:30:00 GMT</pubDate>
      <description>Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating</description>
    </item>
    <item>
      <title>Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment</title>
      <link>https://6ix.com/company/brainsway-ltd/news/landmark-data-validate-brainsways-swifttm-deep-tms-beginning-a-new-era-in-depression-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/landmark-data-validate-brainsways-swifttm-deep-tms-beginning-a-new-era-in-depression-treatment</guid>
      <pubDate>Wed, 04 Mar 2026 12:30:00 GMT</pubDate>
      <description>World’s only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70%BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The milestone advances BrainsWay’s brain health vision and sets the stage for a neuromodulation platform that transf</description>
    </item>
    <item>
      <title>BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-11-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-11-2026</guid>
      <pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss th</description>
    </item>
    <item>
      <title>BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-to-participate-in-the-citi-2026-unplugged-medtech-and-life-sciences-access-day</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-to-participate-in-the-citi-2026-unplugged-medtech-and-life-sciences-access-day</guid>
      <pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is</description>
    </item>
    <item>
      <title>BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-announces-new-minority-stake-investment-in-canadian-provider-brainstim-health-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-announces-new-minority-stake-investment-in-canadian-provider-brainstim-health-inc</guid>
      <pubDate>Thu, 19 Feb 2026 12:30:00 GMT</pubDate>
      <description>BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health</description>
    </item>
    <item>
      <title>BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-reports-cigna-evernorth-behavioral-123000606</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-reports-cigna-evernorth-behavioral-123000606</guid>
      <pubDate>Wed, 18 Feb 2026 12:30:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers</description>
    </item>
    <item>
      <title>BrainsWay Announces Change in ADS-to-Ordinary Share Ratio</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-announces-change-ads-ordinary-123000678</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-announces-change-ads-ordinary-123000678</guid>
      <pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
      <description>Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investorsBURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) lis</description>
    </item>
    <item>
      <title>BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-announces-draft-coverage-policy-123000649</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-announces-draft-coverage-policy-123000649</guid>
      <pubDate>Wed, 21 Jan 2026 12:30:00 GMT</pubDate>
      <description>New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Highmark Blue Cross Blue Shield®, a company with over seven million covered lives that primarily serves Pennsylvania, Delaware, West Virginia, and parts of New Y</description>
    </item>
    <item>
      <title>BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-announces-fda-approval-neurolief-123000248</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-announces-fda-approval-neurolief-123000248</guid>
      <pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
      <description>BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressantsBURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (F</description>
    </item>
    <item>
      <title>BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-announces-first-coverage-policy-123000260</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-announces-first-coverage-policy-123000260</guid>
      <pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
      <description>New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Premera Blue Cross Blue Shield®, a company with over 2.8 million covered lives serving Alaska and Washington state, has adopted a new final medical policy which, among othe</description>
    </item>
    <item>
      <title>BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-reports-expansion-adolescent-depression-123000653</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-reports-expansion-adolescent-depression-123000653</guid>
      <pubDate>Mon, 22 Dec 2025 12:30:00 GMT</pubDate>
      <description>Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and OlderBURLINGTON, Mass. and JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Optum Behavioral Health, a leading health services company with over 48 million</description>
    </item>
    <item>
      <title>BrainsWay to Host Virtual Analyst &amp; Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-host-virtual-analyst-investor-123000785</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-host-virtual-analyst-investor-123000785</guid>
      <pubDate>Tue, 25 Nov 2025 12:30:00 GMT</pubDate>
      <description>BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst &amp; Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay’s growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer</description>
    </item>
    <item>
      <title>BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-launches-first-clinical-trial-123000060</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-launches-first-clinical-trial-123000060</guid>
      <pubDate>Mon, 17 Nov 2025 12:30:00 GMT</pubDate>
      <description>Multicenter, randomized, controlled study will evaluate Company’s next-generation multichannel TMS technology in reducing heavy drinking and cravingsBURLINGTON, Mass. and JERUSALEM, Nov. 17, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced the launch of a multicenter clinical trial investigating the use of its novel Deep TMS 360™ system in individuals with Alcohol</description>
    </item>
    <item>
      <title>BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-receives-fda-clearance-deep-110000205</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-receives-fda-clearance-deep-110000205</guid>
      <pubDate>Thu, 13 Nov 2025 11:00:00 GMT</pubDate>
      <description>Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depressionBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted a label expansion for the Deep Transcranial Magnetic Stimulation (</description>
    </item>
    <item>
      <title>BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-reports-third-quarter-2025-123000184</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-reports-third-quarter-2025-123000184</guid>
      <pubDate>Tue, 11 Nov 2025 12:30:00 GMT</pubDate>
      <description>Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mas</description>
    </item>
    <item>
      <title>BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder</title>
      <link>https://6ix.com/company/brainsway-ltd/news/brainsway-reports-national-institutes-health-130000884</link>
      <guid isPermaLink="true">https://6ix.com/company/brainsway-ltd/news/brainsway-reports-national-institutes-health-130000884</guid>
      <pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
      <description>New NIH grant awards $2.5 million over 5 years for mechanistic studyBURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded a new grant – totaling approximately $2.5 million over five years – to a research team led by Principal Investigator Dr.</description>
    </item>
  </channel>
</rss>